Cancer Genetics, Inc.
https://www.cancergenetics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cancer Genetics, Inc.
Regenerative Medicine Comes Of Age – In The Age Of COVID-19
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics
The latest biopharma industry appointments include CEOs for Stada and Astellas, a finance chief for Novo Nordisk and a new president for Boehringer Ingelheim in the US, while Orchard Therapeutics has made a key addition to its scientific advisory board.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
-
Laboratory Testing Services
- Esoteric Laboratories
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Bio Type, Inc.
- Gentris Corporation
- Pathwork Diagnostics
- Response Genetics, Inc.
- vivoPharm Pty. Ltd.